Biogen Inc. (NASDAQ:BIIB) – Research analysts at Jefferies Group lowered their Q4 2017 earnings per share estimates for shares of Biogen in a research note issued to investors on Tuesday, Zacks Investment Research reports. Jefferies Group analyst M. Yee now anticipates that the biotechnology company will earn $5.36 per share for the quarter, down from their previous estimate of $5.59. Jefferies Group also issued estimates for Biogen’s Q1 2018 earnings at $5.97 EPS, Q2 2018 earnings at $6.21 EPS, Q3 2018 earnings at $6.24 EPS and Q4 2018 earnings at $6.23 EPS.
A number of other analysts also recently issued reports on BIIB. BMO Capital Markets reissued a “hold” rating and set a $318.00 target price on shares of Biogen in a research report on Tuesday, July 18th. Goldman Sachs Group, Inc. (The) raised shares of Biogen from a “neutral” rating to a “buy” rating and increased their target price for the stock from $228.00 to $338.00 in a research report on Wednesday, July 26th. Leerink Swann reissued a “market perform” rating and set a $338.00 target price (up previously from $304.00) on shares of Biogen in a research report on Wednesday, July 26th. Deutsche Bank AG reissued a “buy” rating and set a $319.00 target price (up previously from $315.00) on shares of Biogen in a research report on Wednesday, July 26th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $311.00 target price (up previously from $301.00) on shares of Biogen in a research report on Wednesday, July 26th. Twelve equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. Biogen currently has a consensus rating of “Buy” and a consensus target price of $341.89.
COPYRIGHT VIOLATION NOTICE: This piece was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/11/12/biogen-inc-forecasted-to-earn-q4-2017-earnings-of-5-36-per-share-biib.html.
Shares of Biogen (NASDAQ BIIB) opened at $310.44 on Thursday. The stock has a market cap of $65,650.92, a P/E ratio of 14.38, a P/E/G ratio of 1.94 and a beta of 0.72. Biogen has a 1 year low of $244.28 and a 1 year high of $348.84. The company has a current ratio of 2.19, a quick ratio of 1.90 and a debt-to-equity ratio of 0.46.
Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Tuesday, October 24th. The biotechnology company reported $6.31 EPS for the quarter, beating the Zacks’ consensus estimate of $5.70 by $0.61. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The company had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter in the prior year, the company posted $5.19 EPS. The company’s quarterly revenue was up 4.1% compared to the same quarter last year.
Large investors have recently added to or reduced their stakes in the stock. Pathstone Family Office LLC acquired a new position in shares of Biogen in the 1st quarter valued at $102,000. Prentiss Smith & Co. Inc. boosted its position in shares of Biogen by 14.9% in the 2nd quarter. Prentiss Smith & Co. Inc. now owns 385 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 50 shares during the period. Atlantic Trust LLC acquired a new position in shares of Biogen in the 2nd quarter valued at $114,000. Independent Portfolio Consultants Inc. boosted its position in shares of Biogen by 93.2% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 454 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 219 shares during the period. Finally, Winfield Associates Inc. boosted its position in shares of Biogen by 16.8% in the 1st quarter. Winfield Associates Inc. now owns 467 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 67 shares during the period. Institutional investors and hedge funds own 87.76% of the company’s stock.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Get a free copy of the Zacks research report on Biogen (BIIB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.